Unasnemab

DB18837InvestigationalProtein Based Therapies

Unasnemab is under investigation in clinical trial NCT04683848 (Study to Assess the Efficacy and Safety of MT-3921 in Subjects With Acute Traumatic Cervical Spinal Cord Injury).

Mechanism: Pharmacologically active on Repulsive guidance molecule A
Curator reviewed
Also known as: Immunoglobulin g1, anti-(human repulsive guidance molecule rgma) (human-mus musculus clone rh116a3 .gamma.1-chain), disulfide with human-mus musculus clone rh116a3 .kappa.-chain, dimer
Code names: MT-3921

Resolves to

Compound

UNIIXB2155292YCAS2379805-59-9

Targets

Q96B86RGMA

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

4Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Unasnemab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account